Tesidolumab

N/A

Report date: 2024/09/19 20:00:08

Base Information

Drug NameTesidolumab
Drug Alias NameLFG-316NOV-4
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionComplement C5 modulators
TargetsComplement C5
Therapy Area/IndicationsRejection of renal transplantationHemoglobinuria, ParoxysmalUveitis, Intermediate +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMorphosys AgNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesNovartis Institutes For Biomedical Research IncAlcon
Active IndicationsHemoglobinuria, Paroxysmal
Inactive IndicationsRejection of renal transplantationUveitis, IntermediateUveitis, Posterior +[7] 

Other Information

ATC CodeN/A
Related LinksN/A